MAR-T Technology and Platform - MAR-T cells recognize up to 6 antigens for a potent anti-tumor response[18] - MAR-T cells lack genetic modification, posing no mutagenesis risk[18] - The MAR-T platform technology was developed at Baylor College of Medicine[18] - Marker Therapeutics was awarded over $30 million in non-dilutive funding to date[14] MT-601 (APOLLO Study) - MT-601 targets 6 tumor-specific antigens for broad tumor recognition[13, 17] - MT-601 in Phase 1 clinical trial has shown a 78% response rate in lymphoma patients who relapsed after anti-CD19 CAR-T cells or where CAR-T cell therapy is not an option[13] - In the APOLLO study, 7 out of 9 patients (78%) achieved objective responses at the first response assessment[31, 37] - 4 patients (44.4%) demonstrated complete response (CR) at first assessment in the APOLLO study[31] - MT-601 is an optimized MAR-T cell product with 4x increased potency compared to the Baylor study[27] Future Developments - The FDA granted an IND to investigate MT-401 in an "Off-the-Shelf" setting (MT-401-OTS) in AML or Myelodysplastic Syndrome (MDS)[36] - The FDA has granted an IND to investigate MT-601 in patients with metastatic pancreatic cancer in combination with front-line chemotherapy[36]